2024 Intervention Selection & Sequencing in Early Stage NSCLC

Total Health

J. Porter

ASCO® 2024 Lung Cancer Highlights: Top Abstracts Including BEAT-SC, …

2024 ASCO® Annual Meeting Insights Hub

B. Halmos

Updates in the Management of NSCLC: Systemic Therapy Year in Review

Total Health

W. Iams

Hyperprogression in Cancer Treated With Immunotherapy

Northwestern Medicine Oncology and Hematology

Y. Chae

Metastatic EGFRm NSCLC: 1L Therapy Options

University of Colorado Cancer Center

T. Patil

ESMO 2024 Summary: Management of Oligoprogressive Disease - Patients…

2024 ESMO Annual Meeting Insights Hub

R. Van den Begin

Recent NSCLC Updates Including PAPILLON, CHECKMATE 77T, and KEYNOTE-…

ecancer

L. Raez

ASCO® 2024 Lung Cancer Roundtable: Advances in NSCLC

ecancer

E. Felip, A. Spira, A. Passaro, A. Addeo

Controversies in NSCLC: Neoadjuvant vs. Adjuvant IO in Early Stage D…

Luis Raez

Duration of Immunotherapy Beyond 2 Years for Patients With Advanced …

IASLC Targeted Therapies of Lung Cancer 2023 Conference Coverage

E. Rodriguez

Checkpoint Inhibitors, Arthritis and Other Autoimmune Triggers

West Virginia State Rheumatology Society

J. Bustamante

Photodynamic Therapy for Malignant Airway Disease

Fayez Kheir

WCLC 2024 Insights: Adjuvant vs. Neoadjuvant vs. Peri-Operative Ther…

Insights from 2024 WCLC

J. Von Der Thusen

PACIFIC Trial 5-Year OS Data: Clinical Implications in NSCLC

John Conibear

ASCO® 2023 Insights: "KEYNOTE-671 Trial Key Learnings & Clinical Imp…

Insights from 2023 ASCO® Annual Meeting

J. West

Developmental Therapeutics Highlights From ASCO® 2024

2024 ASCO® Annual Meeting Insights Hub

G. Sonpavde

Treatment Updates in Early Stage NSCLC - Advances in Thoracic Oncolo…

Total Health

J. Porter

Respiratory Tract, EBUS, Molecular Biomarker Testing in Non-Small Ce…

Houston Methodist

S. Roy-Chowdhuri

Management of mNSCLC Without Actionable Mutations

Integrity CE

M. Baumgart, S. Liu